Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch AI could spot diabetes clues without needles

NCT ID NCT05482958

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether a smartwatch, combined with artificial intelligence, could identify digital signs of type 2 diabetes. Researchers gave 210 adults a multisensor watch to track heart rate and other vitals, then analyzed the data with machine learning. The goal was to find patterns linked to diabetes and blood sugar control, potentially leading to simpler, non-invasive monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HOP watch (multisensor smartwatch)
What this could lead to
If successful, this could lead to a non-invasive way to monitor diabetes using a smartwatch, helping doctors and patients manage the condition more easily.
What could go wrong
This was a small, completed study focused on finding patterns, not testing a treatment. The results may not apply to all patients or lead to a practical tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

210 people

The number who actually took part.

Started

Jul 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators will recruit participants with T2DM (case group; n=90) and without T2DM (control group; n=120), calculated as per the method for sufficient statistical classification power (Protocol v4.0)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 years 2. Able to follow-up with study protocol schedule 3. Life expectancy \> 1 year 4. Case group only a. HbA1c \>= 6.5% or is diagnosed with T2DM Exclusion Criteria: 1. Any person who does not meet the above criteria or who refuses to participate 2. Undergoing chemotherapy or dialysis 3. Currently in palliative care 4. Any person who does not have an email address 5. Control group only a. HbA1c \>= 6.5% or is diagnosed with T2DM

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • McGill University health Center

    Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.